Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
Researchers have developed a plasma-based disinfectant generated with the help of cold atmospheric pressure plasma (CAP) which could act as a green decontaminant for Covid-19
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
The peptide-based vaccine induces a t cell-dependent response
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Subscribe To Our Newsletter & Stay Updated
